NAYZILAM

LOE Approaching

midazolam

NDANASALSPRAY
Approved
May 2019
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.

Pharmacologic Class:

Benzodiazepine

Indications (1)

Clinical Trials (5)

NCT07340190Phase 1Not Yet Recruiting

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Started May 2026
24 enrolled
Advanced Malignancies
NCT07435194Phase 1Not Yet Recruiting

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

Started Mar 2026
28 enrolled
Healthy
NCT07372625Phase 1Not Yet Recruiting

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Started Jan 2026
NCT07190430Phase 1Active Not Recruiting

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Started Oct 2025
16 enrolled
Atopic Dermatitis
NCT07020988Phase 1Completed

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Started Jun 2025
55 enrolled
Healthy Participants

Loss of Exclusivity

LOE Date
Jan 18, 2028
22 months away
Patent Expiry
Jan 18, 2028
Exclusivity Expiry
May 17, 2026

Patent Records (4)

Patent #ExpiryTypeUse Code
8217033
Jan 18, 2028
Product
U-2526
8809322
Jan 18, 2028
Product
9289432
Jan 18, 2028
Product
U-2526
9687495
Jan 18, 2028
Product
U-2526